Boston Scientific Shares Fall on Weak Preliminary Sales Numbers -- Update
January 14 2020 - 11:10AM
Dow Jones News
By Colin Kellaher and Allison Prang
Medical-device maker Boston Scientific Corp. reported
preliminary fourth-quarter results that fell shy of Wall Street's
expectations, sending shares down more than 7%.
Boston Scientific said Tuesday it expects to report sales of
$2.9 billion, up 13% from a year earlier but below the $2.93
billion analysts polled by FactSet were expecting.
The Marlborough, Mass., company -- which makes medical devices
such as catheters to defibrillators -- had expected sales growth of
13% to 15% for the quarter.
The company said organic sales -- which exclude the impact of
recent deals and foreign currency fluctuations -- rose 7.3%,
missing the company's growth forecast of 8% to 9%.
Investors are focused on the company's sales growth and analysts
were looking for about 9% growth in organic sales for the quarter,
said Danielle Antalffy, an analyst at SVB Leerink, in a research
note. She added, however, that she believes the company is one of
the most attractive opportunities in the medical technology space,
with several new products coming this year.
Despite the sales shortfall, Boston Scientific said it still
expects to report adjusted earnings of 42 cents to 45 cents a share
for the quarter. Analysts polled by FactSet, on average, are
expecting an adjusted profit of 44 cents a share.
The company also said it expects its unadjusted earnings to
exceed its expectations of 22 cents a share to 25 cents a
share.
Boston Scientific reports its fourth-quarter financial results
Feb. 5.
Write to Colin Kellaher at colin.kellaher@wsj.com and Allison
Prang at allison.prang@wsj.com
(END) Dow Jones Newswires
January 14, 2020 10:55 ET (15:55 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Apr 2023 to Apr 2024
